Helicobacter Pylori (H. Pylori) Diagnostics Market Size, Share and Growth Outlook, 2026

Helicobacter Pylori (H. Pylori) Diagnostics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Helicobacter Pylori (H. Pylori) Diagnostics Market size is forecast to increase from $1002.92 Million in 2026 to $2118.78 Million in 2034 at a CAGR of 9.8% between 2026 and 2034.

The Helicobacter Pylori (H. Pylori) Diagnostics market report provides detailed analysis and outlook of Helicobacter Pylori (H. Pylori) Diagnostics segments including By Test Type (Non-Invasive Tests, Invasive Tests, Molecular Diagnostics ), By Product Type (Diagnostic Kits & Consumables, Instruments & Analyzers, Reagents & Test Strips), By Technology (Immunoassays, Point-of-Care (POC) Testing, Isothermal Amplification Technology), By End-User (Diagnostic Laboratories, Hospitals & Clinics, Ambulatory Care Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Helicobacter Pylori (H. Pylori) Diagnostics Industry Overview

Clinical Guidelines Strengthen Standardization in H. Pylori Testing

The Helicobacter pylori (H. pylori) diagnostics industry is evolving as healthcare providers place increasing emphasis on accurate detection, risk stratification, and targeted treatment of one of the most common bacterial infections associated with gastrointestinal disease. H. pylori infection remains a major contributor to peptic ulcer disease, chronic gastritis, and gastric cancer risk, making early and reliable diagnosis a critical component of patient management. The introduction of updated medical necessity and coverage guidelines has strengthened the standardization of diagnostic pathways across healthcare systems. Effective clinical guidance now defines specific criteria under which diagnostic testing qualifies for medical coverage, including the presence of alarm symptoms, peptic ulcer disease, and a family history of gastric cancer. These standards help clinicians determine the appropriate use of biopsy-based testing, urea breath testing, and stool antigen testing while supporting evidence-based patient care.

Molecular Diagnostics Transform H. Pylori Detection Strategies

The diagnostic landscape is increasingly shifting toward advanced molecular technologies that provide greater clinical insight than traditional testing methods. Industry adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) platforms continues to expand as healthcare providers seek more comprehensive diagnostic information. Unlike conventional serological testing, molecular diagnostics can identify genetic markers associated with antibiotic resistance, a growing challenge in H. pylori eradication therapy. As resistance to commonly prescribed antimicrobial agents becomes more prevalent, the ability to characterize resistant bacterial strains is becoming essential for selecting effective treatment regimens. This transition toward precision diagnostics is supporting more personalized treatment approaches and improving the likelihood of successful eradication outcomes.

Established Diagnostic Platforms Maintain Clinical Relevance

Despite advances in molecular testing, established immunoassay-based diagnostic platforms continue to play an important role within clinical laboratories. Regulatory oversight remains essential to ensuring consistency, reliability, and quality across widely used testing systems. The U.S. Food and Drug Administration continues to manage the regulatory lifecycle of established H. pylori diagnostic products, including immunoassays such as the Immulite H. Pylori IgG platform developed by Diagnostic Products Corp. Ongoing maintenance of regulatory compliance and premarket notification records supports laboratory confidence in these diagnostic tools while ensuring continuity of testing services across healthcare facilities.

Antibiotic Resistance Monitoring Drives Diagnostic Innovation

The growing importance of antimicrobial stewardship is creating new opportunities for innovation within the H. pylori diagnostics industry. Healthcare providers increasingly require diagnostic solutions that not only confirm infection but also provide actionable information regarding bacterial susceptibility patterns. As a result, manufacturers are investing in advanced molecular assays, resistance profiling technologies, and integrated diagnostic platforms capable of supporting treatment selection decisions. The focus on antibiotic resistance monitoring is expected to remain a key driver of product development, laboratory modernization, and clinical adoption across the H. pylori diagnostics market.

Helicobacter Pylori (H. Pylori) Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Helicobacter Pylori (H. Pylori) Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Bio-Rad Laboratories, Inc., Quest Diagnostics Incorporated, Meridian Bioscience, Inc. (SD Biosensor), Biohit Oyj, CerTest BIOTEC, Exalenz Bioscience Ltd., Otsuka Holdings Co., Ltd.. The Helicobacter Pylori (H. Pylori) Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Helicobacter Pylori (H. Pylori) Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Helicobacter Pylori (H. Pylori) Diagnostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Helicobacter Pylori (H. Pylori) Diagnostics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Helicobacter Pylori (H. Pylori) Diagnostics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Helicobacter Pylori (H. Pylori) Diagnostics Market Competitive Benchmarking and Company Analysis

Leading companies in Helicobacter Pylori (H. Pylori) Diagnostics industry include- Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Bio-Rad Laboratories, Inc., Quest Diagnostics Incorporated, Meridian Bioscience, Inc. (SD Biosensor), Biohit Oyj, CerTest BIOTEC, Exalenz Bioscience Ltd., Otsuka Holdings Co., Ltd.. The Helicobacter Pylori (H. Pylori) Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Helicobacter Pylori (H. Pylori) Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Helicobacter Pylori (H. Pylori) Diagnostics market remains one of the strongest-performing segments in the country.
The US Helicobacter Pylori (H. Pylori) Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Helicobacter Pylori (H. Pylori) Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Helicobacter Pylori (H. Pylori) Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Helicobacter Pylori (H. Pylori) Diagnostics markets

Canada's strong Helicobacter Pylori (H. Pylori) Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Helicobacter Pylori (H. Pylori) Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Helicobacter Pylori (H. Pylori) Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Helicobacter Pylori (H. Pylori) Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Helicobacter Pylori (H. Pylori) Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Helicobacter Pylori (H. Pylori) Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Helicobacter Pylori (H. Pylori) Diagnostics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Helicobacter Pylori (H. Pylori) Diagnostics sales through 2034

France Helicobacter Pylori (H. Pylori) Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Helicobacter Pylori (H. Pylori) Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Helicobacter Pylori (H. Pylori) Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Helicobacter Pylori (H. Pylori) Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Helicobacter Pylori (H. Pylori) Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Helicobacter Pylori (H. Pylori) Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Helicobacter Pylori (H. Pylori) Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Helicobacter Pylori (H. Pylori) Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Helicobacter Pylori (H. Pylori) Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Helicobacter Pylori (H. Pylori) Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Helicobacter Pylori (H. Pylori) Diagnostics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Helicobacter Pylori (H. Pylori) Diagnostics Market Segmentation

By Test Type
Non-Invasive Tests
Invasive Tests
Molecular Diagnostics
By Product Type
Diagnostic Kits & Consumables
Instruments & Analyzers
Reagents & Test Strips
By Technology
Immunoassays
Point-of-Care (POC) Testing
Isothermal Amplification Technology
By End-User
Diagnostic Laboratories
Hospitals & Clinics
Ambulatory Care Centers

Top Companies in Helicobacter Pylori (H. Pylori) Diagnostics Industry

Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Quest Diagnostics Incorporated
Meridian Bioscience, Inc. (SD Biosensor)
Biohit Oyj
CerTest BIOTEC
Exalenz Bioscience Ltd.
Otsuka Holdings Co., Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025